TAK-243

SKU: orb1307707

Description

TAK-243

Research Area

Product Categories/Products/Small Molecules,Apoptosis|||Ubiquitination|||NF-κB

Key Properties

• CAS Number: 1450833-55-2
• MW: 519.52
• Purity: 98.93%
• Formula: C₁₉H₂₀F₃N₅O₅S₂
• SMILES: NS(=O)(=O)OC[C@H]1C[C@@H](Nc2ccnc3cc(nn23)-c2cccc(SC(F)(F)F)c2)[C@H](O)[C@@H]1O

Bioactivity

• Target IC50:
  myeloma cell:25-100 nM|panel of cells derived from hematologic and solid tumors:0.006 μM to 1.31 μM (EC50)|OCI-AML2 cells、TEX cells、U937 cells、 NB4 cells:15-40 nM|UBA1:1 nM|MM.1S cells:25 nM
  Read more...
• In Vivo:
  METHODS: To assay antitumor activity in vivo, TAK-243 (12.5 mg/kg twice weekly; or 25 mg/kg once weekly) was administered intravenously for two weeks to SCID mice bearing myeloma MM1.S or MOLP-8. S and MOLP-8 models, twice-weekly administration of 12.5 mg/kg produced 60% and 73% tumor growth inhibition at 14 days. 25 mg/kg produced a greater effect. METHODS: To test the antitumor activity in vivo, TAK-243 (20 mg/kg) was injected intravenously twice weekly into SCID mice bearing the human AML tumor OCI-AML2. RESULTS: TAK-243 significantly delayed tumor growth (T/C=0.02) in mice without toxicity.
  Read more...
• In Vitro:
  METHODS: Seven myeloma cells were treated with TAK-243 (6.25-500 nM) for 24 h. Cell viability was measured by WST-1 Assay. RESULTS: Most myeloma cells are very sensitive to TAK-243 with IC50 of 25-100 nM, e.g. MM1.S cells with IC50 of 25 nM. METHODS: Human colorectal cancer cells HCT-116 were treated with TAK-243 (0.008-1 µM) for 24 h, and the expression levels of target proteins were detected by Western Blot. RESULTS: TAK-243 showed strong selectivity for Sumo and autophagic UBL pathways, and TAK-243 inhibited two E1 enzymes (UBA6 and UAE), which are capable of activating ubiquitin, with equal potency.
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Compound Identifiers

PubChem CID

71715374